The FDA has approved pembrolizumab for the first-line treatment of certain HER2-negative gastric and gastroesophageal junction cancers. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda), in combination with a chemotherapy regimen...
The FDA has approved repotrectinib for certain patients with non-small cell lung cancer harboring a ROS1 mutation or rearrangement. The U.S. Food and Drug Administration (FDA) has approved repotrectinib (Augtyro) for the treatment of...
The FDA has approved another inhibitor of the VEGF receptor family for patients with metastatic, heavily pretreated colorectal cancer. The U.S. Food and Drug Administration (FDA) has approved fruquintinib (Fruzaqla) for adult patients with...
The FDA has approved the immune checkpoint inhibitor pembrolizumab for certain advanced cancers of the biliary tract. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda), in combination with gemcitabine (Gemzar) and...
The FDA has approved the immune checkpoint inhibitor toripalimab for some patients with nasopharyngeal carcinoma. The U.S. Food and Drug Administration (FDA) has approved toripalimab-tpzi (Loqtorzi), in combination with the chemotherapies gemcitabine (Gemzar) and...
The FDA has approved the IDH1 inhibitor ivosidenib for a group of blood cancers harboring an IDH1 mutation. The U.S. Food and Drug Administration (FDA) has approved ivosidenib (Tibsovo) for the treatment of relapsed...
The FDA has approved the inhibitor entrectinib for some patients 1 month of age or older with solid tumors harboring a certain genetic mutation. The U.S. Food and Drug Administration (FDA) has granted accelerated...
The FDA has approved pembrolizumab for the treatment of certain surgically removable tumors before and after resection. The U.S. Food and Drug Administration (FDA) has approved the immunotherapy pembrolizumab (Keytruda) for use in combination...
The FDA approved nivolumab for some patients with melanoma whose tumor was completely removed through surgery and has not spread. The U.S. Food and Drug Administration (FDA) has approved the checkpoint inhibitor nivolumab (Opdivo)...
The FDA approved encorafenib with binimetinib as a treatment for certain patients with non-small cell lung cancer. The U.S. Food and Drug Administration has approved encorafenib (Braftovi) with binimetinib (Mektovi) to treat adult patients...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More